Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03067181




Registration number
NCT03067181
Ethics application status
Date submitted
14/02/2017
Date registered
1/03/2017
Date last updated
15/08/2024

Titles & IDs
Public title
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Scientific title
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Secondary ID [1] 0 0
NCI-2017-00178
Secondary ID [2] 0 0
AGCT1531
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Childhood Extracranial Germ Cell Tumor 0 0
Extragonadal Embryonal Carcinoma 0 0
Germ Cell Tumor 0 0
Malignant Germ Cell Tumor 0 0
Malignant Ovarian Teratoma 0 0
Stage I Ovarian Choriocarcinoma 0 0
Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 0 0
Stage I Ovarian Teratoma AJCC v6 and v7 0 0
Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 0 0
Stage I Testicular Choriocarcinoma AJCC v6 and v7 0 0
Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 0 0
Stage I Testicular Seminoma AJCC v6 and v7 0 0
Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 0 0
Stage II Ovarian Choriocarcinoma 0 0
Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 0 0
Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 0 0
Stage II Testicular Choriocarcinoma AJCC v6 and v7 0 0
Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 0 0
Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 0 0
Stage III Ovarian Choriocarcinoma 0 0
Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 0 0
Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 0 0
Stage III Testicular Choriocarcinoma AJCC v6 and v7 0 0
Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 0 0
Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 0 0
Stage IV Ovarian Choriocarcinoma 0 0
Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 0 0
Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 0 0
Testicular Mixed Choriocarcinoma and Embryonal Carcinoma 0 0
Testicular Mixed Choriocarcinoma and Teratoma 0 0
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Ovarian and primary peritoneal
Cancer 0 0 0 0
Testicular
Cancer 0 0 0 0
Other cancer types
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)
Reproductive Health and Childbirth 0 0 0 0
Fetal medicine and complications of pregnancy

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Best Practice
Treatment: Surgery - Biopsy
Treatment: Surgery - Biospecimen Collection
Treatment: Other - Bleomycin Sulfate
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Surgery - Computed Tomography
Treatment: Drugs - Etoposide
Treatment: Surgery - Magnetic Resonance Imaging
Other interventions - Pharmacogenomic Study
Treatment: Surgery - Pulmonary Function Test
Other interventions - Quality-of-Life Assessment
Other interventions - Questionnaire Administration

Experimental: Arm I (bleomycin, carboplatin, etoposide) - Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.

Experimental: Arm II (bleomycin, etoposide, cisplatin) - Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.

Experimental: Arm III (bleomycin, etoposide, carboplatin) - Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.

Experimental: Arm IV (bleomycin, etoposide, cisplatin) - Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.

Experimental: Low-Risk (observation) - Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial.


Other interventions: Best Practice
Undergo observation

Treatment: Surgery: Biopsy
Undergo a tumor biopsy

Treatment: Surgery: Biospecimen Collection
Undergo blood sample collection

Treatment: Other: Bleomycin Sulfate
Given IV

Treatment: Drugs: Carboplatin
Given IV

Treatment: Drugs: Cisplatin
Given IV

Treatment: Surgery: Computed Tomography
Undergo a CT scan

Treatment: Drugs: Etoposide
Given IV

Treatment: Surgery: Magnetic Resonance Imaging
Undergo MRI

Other interventions: Pharmacogenomic Study
Correlative studies

Treatment: Surgery: Pulmonary Function Test
Undergo a pulmonary function test

Other interventions: Quality-of-Life Assessment
Ancillary studies

Other interventions: Questionnaire Administration
Ancillary studies
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Surgery
Intervention code [3] 0 0
Treatment: Other
Intervention code [4] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
Two years post enrollment
Primary outcome [2] 0 0
Event-free survival
Timepoint [2] 0 0
Two years post enrollment
Secondary outcome [1] 0 0
Proportion of participants with hearing loss
Timepoint [1] 0 0
8 weeks after the last dose of platin therapy
Secondary outcome [2] 0 0
Number of participants by understanding score category in the Adolescents and Young Adults-Hearing Screen
Timepoint [2] 0 0
Baseline

Eligibility
Key inclusion criteria
* There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT [all sites])
* Standard risk 1: Patients must be < 11 years of age at enrollment
* Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment
* Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with metastatic germ cell tumor (stage II or higher); histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment except for those who were initially diagnosed with stage I non-seminoma malignant GCT and later recur during observation post surgery off study; for these patients, if elevated tumor markers rise to > 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart, a diagnostic biopsy is not required for enrollment
* Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma (may contain microscopic foci of yolk sac tumor), mixed immature and mature teratoma, (no pathological evidence of MGCT); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages
* Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages
* Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages
* Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV (International Germ Cell Consensus Classification [IGCCC] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) < 11
* Standard risk 2 (SR2)

* Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25
* Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; tumor markers: must be IGCCC good risk; post op: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 3.0 x normal; age (years) >= 11 and < 25
* Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25
* Notes:

* IGCCC criteria only apply to SR2 patients with a testicular primary tumor
* Use post-op tumor marker levels to determine IGCCC risk group
* Stage 1 seminoma patients are not eligible for the standard risk arms of the study
* For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a "microscopic component" of yolk sac tumor
* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
* Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients)
* Adequate renal function defined as:
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to enrollment) OR
* A serum creatinine based on age/gender as follows (within 7 days prior to enrollment): (mg/dL)

* 1 month to < 6 months male: 0.4 female: 0.4
* 6 months to < 1 year male: 0.5 female: 0.5
* 1 to < 2 years male: 0.6 female: 0.6
* 2 to < 6 years male: 0.8 female: 0.8
* 6 to < 10 years male: 1 female: 1
* 10 to < 13 years male: 1.2 female: 1.2
* 13 to < 16 years: male: 1.5 female: 1.4
* >= 16 years male: 1.7 female: 1.4
* Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)
* Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age (for the purpose of this study, the ULN for SGPT is 45 U/L) (within 7 days prior to enrollment)
* Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3 (within 7 days prior to enrollment) AND
* Platelet count >= 100,000/mm^3 (within 7 days prior to enrollment)
* Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment
* Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes [PROs] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate
* >= 11 and < 25 years old at enrollment
* Able to fluently speak and read English
* Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor
* Followed for cancer or survivorship care at one of the following institutions:

* Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
* Dana Farber/Harvard Cancer Center
* Hospital for Sick Children
* Children's Hospital of Eastern Ontario
* Oregon Health and Science University
* Seattle Children's Hospital
* Yale University
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with any diagnoses not listed including:

* Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection)
* Pure dysgerminoma
* Pure mature teratoma
* Pure immature teratoma COG stage I, grade I
* Pure immature teratoma COG stage I, grade 2,3 with alpha-fetoprotein (AFP) >= 1000 ng/mL
* Pure immature teratoma COG stage II - IV or FIGO stage IC to IV
* "Poor risk" GCT (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or
* Primary central nervous system (CNS) germ cell tumor
* Germ cell tumor with somatic malignant transformation
* Spermatocytic seminoma
* Patients must have had no prior systemic therapy for the current cancer diagnosis
* Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain [stage IV disease] would be considered poor risk and therefore not eligible for this trial)
* Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
* Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/05/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/06/2027
Actual
Sample size
Target
2097
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [3] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [4] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 0 0
Monash Medical Center-Clayton Campus - Clayton
Recruitment hospital [6] 0 0
Royal Children's Hospital - Parkville
Recruitment hospital [7] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment hospital [8] 0 0
Perth Children's Hospital - Perth
Recruitment postcode(s) [1] 0 0
2310 - Hunter Regional Mail Centre
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3052 - Parkville
Recruitment postcode(s) [7] 0 0
6008 - Perth
Recruitment postcode(s) [8] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
Arkansas
Country [5] 0 0
United States of America
State/province [5] 0 0
California
Country [6] 0 0
United States of America
State/province [6] 0 0
Colorado
Country [7] 0 0
United States of America
State/province [7] 0 0
Connecticut
Country [8] 0 0
United States of America
State/province [8] 0 0
Delaware
Country [9] 0 0
United States of America
State/province [9] 0 0
District of Columbia
Country [10] 0 0
United States of America
State/province [10] 0 0
Florida
Country [11] 0 0
United States of America
State/province [11] 0 0
Georgia
Country [12] 0 0
United States of America
State/province [12] 0 0
Hawaii
Country [13] 0 0
United States of America
State/province [13] 0 0
Idaho
Country [14] 0 0
United States of America
State/province [14] 0 0
Illinois
Country [15] 0 0
United States of America
State/province [15] 0 0
Indiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Iowa
Country [17] 0 0
United States of America
State/province [17] 0 0
Kentucky
Country [18] 0 0
United States of America
State/province [18] 0 0
Louisiana
Country [19] 0 0
United States of America
State/province [19] 0 0
Maine
Country [20] 0 0
United States of America
State/province [20] 0 0
Maryland
Country [21] 0 0
United States of America
State/province [21] 0 0
Massachusetts
Country [22] 0 0
United States of America
State/province [22] 0 0
Michigan
Country [23] 0 0
United States of America
State/province [23] 0 0
Minnesota
Country [24] 0 0
United States of America
State/province [24] 0 0
Mississippi
Country [25] 0 0
United States of America
State/province [25] 0 0
Missouri
Country [26] 0 0
United States of America
State/province [26] 0 0
Montana
Country [27] 0 0
United States of America
State/province [27] 0 0
Nebraska
Country [28] 0 0
United States of America
State/province [28] 0 0
Nevada
Country [29] 0 0
United States of America
State/province [29] 0 0
New Hampshire
Country [30] 0 0
United States of America
State/province [30] 0 0
New Jersey
Country [31] 0 0
United States of America
State/province [31] 0 0
New Mexico
Country [32] 0 0
United States of America
State/province [32] 0 0
New York
Country [33] 0 0
United States of America
State/province [33] 0 0
North Carolina
Country [34] 0 0
United States of America
State/province [34] 0 0
North Dakota
Country [35] 0 0
United States of America
State/province [35] 0 0
Ohio
Country [36] 0 0
United States of America
State/province [36] 0 0
Oklahoma
Country [37] 0 0
United States of America
State/province [37] 0 0
Oregon
Country [38] 0 0
United States of America
State/province [38] 0 0
Pennsylvania
Country [39] 0 0
United States of America
State/province [39] 0 0
Rhode Island
Country [40] 0 0
United States of America
State/province [40] 0 0
South Carolina
Country [41] 0 0
United States of America
State/province [41] 0 0
South Dakota
Country [42] 0 0
United States of America
State/province [42] 0 0
Tennessee
Country [43] 0 0
United States of America
State/province [43] 0 0
Texas
Country [44] 0 0
United States of America
State/province [44] 0 0
Utah
Country [45] 0 0
United States of America
State/province [45] 0 0
Vermont
Country [46] 0 0
United States of America
State/province [46] 0 0
Virginia
Country [47] 0 0
United States of America
State/province [47] 0 0
Washington
Country [48] 0 0
United States of America
State/province [48] 0 0
West Virginia
Country [49] 0 0
United States of America
State/province [49] 0 0
Wisconsin
Country [50] 0 0
Canada
State/province [50] 0 0
Alberta
Country [51] 0 0
Canada
State/province [51] 0 0
British Columbia
Country [52] 0 0
Canada
State/province [52] 0 0
Manitoba
Country [53] 0 0
Canada
State/province [53] 0 0
Newfoundland and Labrador
Country [54] 0 0
Canada
State/province [54] 0 0
Nova Scotia
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Canada
State/province [56] 0 0
Quebec
Country [57] 0 0
India
State/province [57] 0 0
Mumbai
Country [58] 0 0
Japan
State/province [58] 0 0
Aoba-ku
Country [59] 0 0
Japan
State/province [59] 0 0
Chiba
Country [60] 0 0
Japan
State/province [60] 0 0
Chuo-ku
Country [61] 0 0
Japan
State/province [61] 0 0
Fukuoka
Country [62] 0 0
Japan
State/province [62] 0 0
Hokkaido
Country [63] 0 0
Japan
State/province [63] 0 0
Hyogo
Country [64] 0 0
Japan
State/province [64] 0 0
Ibaraki
Country [65] 0 0
Japan
State/province [65] 0 0
Kanagawa
Country [66] 0 0
Japan
State/province [66] 0 0
Saitama
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Hiroshima City
Country [69] 0 0
Japan
State/province [69] 0 0
Kyoto
Country [70] 0 0
Japan
State/province [70] 0 0
Nishinomiya, Hyogo
Country [71] 0 0
Japan
State/province [71] 0 0
Osaka City
Country [72] 0 0
New Zealand
State/province [72] 0 0
Auckland
Country [73] 0 0
New Zealand
State/province [73] 0 0
Christchurch
Country [74] 0 0
Puerto Rico
State/province [74] 0 0
Caguas
Country [75] 0 0
Puerto Rico
State/province [75] 0 0
San Juan
Country [76] 0 0
Saudi Arabia
State/province [76] 0 0
Riyadh
Country [77] 0 0
United Kingdom
State/province [77] 0 0
England
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Scotland

Funding & Sponsors
Primary sponsor type
Other
Name
Children's Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
A. L Frazier
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03067181